Dynavax Provides Regulatory Update on sBLA for HEPLISAV-B Four-Dose Regimen for Adults on Hemodialysis in the US
EMERYVILLE, California, May 14, 2024 /PRNewswire/ — Dynavax Technologies Corporation (Nasdaq: DVAX) today provided a regulatory update for the company’s Supplemental Biologics License Application (sBLA) to include a four-dose HEPLISAV-B …
